What were the key takeaways from Phathom’s earnings call?

What is Phathom's latest dividend and current dividend yield?

What guidance did Phathom's management provide for the next earnings period?

What is Phathom's gross profit margin?

What does Phathom do and what are its main business segments?

What were the key takeaways from Phathom's earnings call?

What is the revenue and EPS growth rate for Phathom year over year?

What is the market's earnings forecast for Phathom next quarter?

- **Revenue Growth**: 217% YoY increase to $175.1 million, driven by GI strategy and 1.1M prescriptions.
- **Capital Structure**: Extended term loan maturity to 2029, reduced interest rate to 9.85%, and raised $130M via equity offering.
- **Sales Force Strength**: 285/300 reps on board, 2,000+ top-tier GI adopters, and 64% Q4 scripts covered by insurance.
- **Competitive Position**: Confident in VOQUEZNA's leadership despite second P-CAB entrant, with 65M GERD patients eligible for P-CABs.

**【CEO Summary Section】**
- **Revenue Growth**: Full year 2025 net revenue of $175.1 million, up 217% year-over-year, driven by GI-focused strategy. Q4 revenue of $57.6 million, in line with preannounced guidance.
- **Capital Structure Enhancements**: Modified term loan to extend maturity to February 2029, reduce interest rate to 9.85%, and lower principal amount. Raised $130 million through January equity offering.
- **GI Strategy Momentum**: 1.1 million VOQUEZNA prescriptions filled by Q4, 273,000 Q4 covered scripts (64% of total), and 65 million GERD patients eligible for P-CABs.
- **2026 Outlook**: Guided revenue of $320-$345 million, operating profitability beginning Q3 2026, and cash flow positivity in 2027.

**【CFO Financial Commentary】**
- **Financial Performance**: Full year 2025 cash operating expenses of $284 million (excluding stock-based comp), down 50% sequentially. Q4 cash operating expenses of $50.3 million, below $55 million target.
- **Gross Margin**: Consistent at 87% for Q4 and full year. 2026 gross margin expected at ~80% due to accounting changes.
- **Liquidity**: $130 million cash on hand post-term loan modification, sufficient to meet obligations under revised debt terms.

**【Q&A Key Highlights】**
- **Sales Force Effectiveness**: 285/300 sales positions filled, focus on GI call points, and 2,000+ physicians in top adoption tiers (up from 400-500 in summer 2025).
- **Medicare Coverage**: Incremental Medicare Part D plans covering VOQUEZNA, with appeals process supporting cash pay prescriptions.
- **Competitive Landscape**: Positive impact of second P-CAB entrant (e.g., Sebela's tegoprazan) expected to expand category awareness, with VOQUEZNA's first-mover advantage.
- **2026 Cadence**: 40% of revenue in first half, 60% in second half, with Q1 seasonality and winter storms impacting near-term growth.

Phathom Pharmaceuticals, Inc.(PHAT)-20260226-2025 Q4 Earnings call transcript

- **Revenue Surge**: 25% QoQ growth to $49.5M, beating expectations, with covered scripts driving 23% expansion.
- **Cost Revolution**: Operating expenses down 43% to $49.3M, cash usage reduced 77% to $14M, positioning for 2026 profitability.
- **GI Dominance**: 70% of scripts from GI, targeting $1B+ annual revenue from 20M PPI scripts. 300-rep sales force expansion by Q1 2026.
- **Pipeline Momentum**: Phase II EoE trial underway, with potential exclusivity extension. Regulatory exclusivity until 2033.
- **Financial Strength**: $135M cash balance, no equity needed through 2026, and plans to refinance debt for flexibility.

**【CEO Summary Section】**
- **Revenue Growth**: Q3 net revenue of $49.5M, up 25% QoQ, driven by covered prescriptions (23% growth) and cash-pay scripts (38% growth). Full year guidance narrowed to $170-175M.
- **Cost Efficiency**: Cash operating expenses reduced to $49.3M (43% QoQ decline), with Q4 OpEx expected below $55M despite Phase II trial costs.
- **GI Strategy**: Shifted focus to gastroenterologists (70% of scripts from GI), targeting 20-30% penetration of 20M annual GI PPI scripts. Sales force realigned to 300 reps by Q1 2026.
- **Pipeline Progress**: Phase II EoE trial underway, with potential 6-month exclusivity extension if successful. Regulatory exclusivity extended to 2033.

**【CFO Financial Commentary】**
- **Financial Health**: Gross profit margin stable at 87%, with $135M cash balance (down $14M QoQ, 77% reduction vs. Q2). Operating loss improved 88% to $6M.
- **Guidance**: 2025 non-GAAP OpEx $280-290M, targeting 2026 operating profitability. Gross to net ratio tightened to 55-60% for Q4.
- **Liquidity**: Current cash suffices through 2026 without equity financing, with plans to refinance debt for flexibility.

**【Q&A Highlights】**
- **Sales Force Transition**: 300 reps by Q1 2026, with Q4 disruption offset by long-term GI growth. Primary care re-engagement contingent on NBRx per call metrics.
- **Medicare Access**: Cash-pay scripts grew 38% QoQ, with no cannibalization of covered scripts. BlinkRx reduces abandonment rates via $25/$50 co-pays.
- **Long-Term Outlook**: 2026 focus on GI penetration, with potential 2027-2028 primary care expansion. Phase II EoE results expected in 2027.

Phathom Pharmaceuticals, Inc. (PHAT) Q3 2025 Earnings Call Transcript

- **Revenue Surge**: Q2 revenue up 39% to $39.5M, driven by 173,000 VOQUEZNA prescriptions (36% QoQ growth). Total prescriptions >580,000 by July 25. 
- **Strategic Shift**: Focused on GI prescribers (70% of scripts), reallocating reps to 20,000 high-potential GI targets. Q3/Q4 OpEx targets: < $60M and < $55M. 
- **Exclusivity Win**: FDA grants exclusivity until 2032, with potential 2033 extension. Phase II EoE trial to begin Q4 for 6-month exclusivity. 
- **Cash & Profitability**: $150M cash to fund 2026 profitability. Full-year 2025 revenue guidance $165-$175M, up from analyst estimates. 
- **Cost Efficiency**: Q2 OpEx down $12M vs. Q1, with $18M savings from DTC ad cuts and vendor restructuring.

**【CEO Summary Section】**
- **Revenue Growth**: Q2 revenue reached $39.5 million, a 39% increase from Q1, driven by VOQUEZNA prescriptions (173,000 in Q2, up 36% from Q1). Total prescriptions exceeded 580,000 by July 25, with 49% growth in 14 weeks. 
- **Sales Strategy Shift**: Focused on gastroenterologists (GI), who account for 70% of prescriptions. Removed 20,000 unproductive PCP targets, reallocating reps to high-potential GI accounts. Q2 GI prescriptions grew 2x faster than PCP. 
- **Exclusivity Extension**: FDA granted exclusivity until May 2032, potentially extended to 2033 with pediatric studies. Phase II EoE trial to begin Q4, targeting 6-month exclusivity extension. 
- **Financial Outlook**: Full-year 2025 revenue guidance of $165-$175 million, up from analyst estimates. Q3 expenses < $60M, Q4 < $55M, with $150M cash to support 2026 profitability. 
- **Supply Chain Update**: 1% revenue-impacting triple pack supply issue resolved; dual pack remains unaffected. 

**【CFO Financial Commentary】**
- **Revenue & Margin**: Q2 gross margin 87%, consistent with prior quarter. Gross-to-net discount rate 55-65%, stable. 
- **Cost Savings**: Q2 non-GAAP OpEx $86.1M, down $12M from Q1. Q3/Q4 targets: < $60M and < $55M, excluding one-time costs. 
- **Cash Position**: $150M cash, sufficient for 2026 profitability with disciplined spending. 
- **Expense Breakdown**: $7.4M R&D (23% YoY), $78.7M SG&A (11% YoY). 

**【Q&A Highlights】**
- **GI Adoption**: Reps now spend >60% of time on GI, with 24% increase in unique HCPs writing scripts. Multiple calls needed to move from trialists to daily adopters. 
- **Cost-Cutting Impact**: Eliminated DTC ads ($15M/Q2) and restructured vendor contracts, with $18M savings offset by $6M one-time costs. 
- **BlinkRx Utilization**: 68% Q2 scripts filled via retail, 32% via Blink (cash pay $50/co-pay $25). Both channels growing, no target ratio. 
- **Pediatric Strategy**: EoE trial may enable 6-month exclusivity extension if successful. No immediate plans for ex-U.S. launches. 
- **Profitability Path**: Anticipate 2026 profitability with current cash and revenue growth, no additional equity needed.

Phathom Pharmaceuticals (PHAT)-7 Aug 25-2025 Q2 Earnings call transcript

- **Cost-Cutting Ambition**: Targeting $55M quarterly expenses by Q4 2025 to achieve 2026 profitability without financing.
- **Sales-Driven Growth**: Maintaining field sales strength, halting low-ROI DTC ads, focusing on digital channels.
- **Exclusivity Criticality**: FDA Citizens Petition response by early June could extend exclusivity to 2032; contingency planning underway.
- **Prescription Momentum**: 390K+ scripts filled YTD (30% growth), 75% repeat patients, 23,600+ prescribers.
- **Cash Management**: $212M cash balance; targeting 2026 breakeven without additional funding.


**【CEO Opening Remarks】**
- **Strategic Shift**: Targeting Q4 2025 operating expenses below $55M quarterly to achieve 2026 profitability without additional financing.
- **Cost Reductions**: 
  - 6% workforce reduction, halting broadcast DTC ads (highest spend category), maintaining digital channels with higher ROI.
  - Pausing Phase 2 eosinophilic esophagitis study pending Citizens Petition outcome.
- **Sales Focus**: Maintaining field sales strength with new SVP Jonathan Bentley (Intra-Cellular/J&J). 
- **Citizens Petition**: FDA response expected by early June; positive outcome would extend exclusivity to 2032. Contingency planning if response is negative or delayed.
- **Manufacturing Update**: Potential TRIPLE PAK supply disruption, but minimal impact as DUAL PAK remains unaffected and TRIPLE PAK contributes <10% revenue.

**【CFO Financial Highlights】**
- **Q1 2025 Results**: 
  - Net revenue: $28.5M (down slightly QoQ due to wholesaler destocking).
  - Gross margin: 87% (stable vs. prior quarter).
  - Non-GAAP loss: $77.1M ($1.07 per share), driven by $90.3M SG&A (including $28.3M DTC spend).
- **Prescription Growth**: 
  - 390K+ scripts filled YTD (30% growth vs. last report), 75% repeat patients.
  - 23,600+ prescribers (30% QoQ increase), 70% scripts via retail pharmacies.
- **Cash Position**: $212M as of Q1, targeting 2026 breakeven without additional financing.

**【Q&A Key Takeaways】**
- **DTC Spend Impact**: Broadcast TV ads not driving new prescribers; field sales remain core growth driver. Digital channels retained for higher ROI.
- **Citizens Petition Timeline**: FDA response expected by early June; contingency plans if delayed.
- ** Pediatric Studies**: Phase 2 EoE study paused; evaluating alternative paths for pediatric exclusivity extension post-Petition decision.
- **Competitive Landscape**: Takeda’s PCAB launch may expand category but VOQUEZNA benefits from first-mover advantage and proven efficacy.
- **Manufacturing Risk**: TRIPLE PAK supply disruption potential, but negligible impact on revenue or operations.


Phathom Pharmaceuticals (PHAT)-1 May 25-2025 Q1 Earnings call transcript

- **Revenue Surge**: Q4 2024 revenue up 81% QoQ to $29.7M, driven by non-erosive GERD approval and DTC campaign.
- **Gross Margin Strength**: 87% gross margin in Q4, narrowing GTN guidance to 55-65% for 2025.
- **Prescription Momentum**: 300,000+ fills, 75% refill rate, and 20,000+ prescribers highlight strong patient adherence.
- **Strategic Growth**: Investing in primary care expansion, EoE trial, and OTC/ODT formulations to unlock $3B OTC market opportunity.
- **IP Confidence**: Citizen petition for 10-year exclusivity on track; robust patent portfolio provides fallback protection.

**【CEO Opening Remarks】**
- **2024 Key Achievements**: Secured broad commercial access, launched consumer campaign, and received FDA approval for non-erosive GERD. Over 300,000 prescriptions filled, with 75% refill rate.
- **2025 Growth Drivers**: Expand DTC marketing, target primary care physicians (PCPs), and explore EoE and OTC opportunities. Believes VOQUEZNA can reach blockbuster status.
- **Citizen Petition Update**: Submitted request for 10-year exclusivity; awaiting FDA response by June 2025. Confident in patent strength, with composition of matter patent expiring in mid-2030s.

**【CFO Financial Highlights】**
- **Q4 2024 Results**: Net revenue $29.7M (81% QoQ growth), gross margin 87%, non-GAAP net loss $56.4M.
- **2025 Guidance**: Revenue consensus $165M; operating expenses $360-390M (R&D: 10%, SG&A: 90%). Gross-to-net (GTN) rate 55-65%.
- **Cash Position**: $297M as of Q4, with $100M available under debt facility.

**【Commercial Officer Updates】**
- **Prescription Growth**: 300,000+ fills (70% QoQ growth in Q4), 75% refill rate, 20,000+ prescribers (45% QoQ increase).
- **Access & Coverage**: >80% commercial coverage (120M+ lives), 75% scripts through retail pharmacies, simple prior authorization process.
- **DTC Campaign Impact**: 55% increase in patient requests, 75% of aware physicians likely to prescribe if asked.

**【Q&A Key Takeaways】**
- **Q1 2025 Softness**: Anticipated due to seasonal factors, but 2025 consensus revenue maintained at $165M.
- **EoE Trial**: Phase 2 design finalized; top-line data expected in 2027.
- **OTC Strategy**: Exploring long-term differentiation; OTC market generates $3B annually, with 35% share for branded PPIs.
- **ODT Formulation**: Development underway for patients with swallowing difficulties; potential IP protection and OTC switch opportunity.
- **Citizen Petition Contingency**: If exclusivity denied, rely on strong patent portfolio (composition of matter, formulation).

Actual			-0.62	-0.64	-1.02	-1.58	-0.96	-1	-0.98	-0.95	-1.07	-1.33	-1.32	-1.33	-0.89	-0.84	-0.76	-1.39	-1.42	-1.56	-1.32	-1.05	-1.31	-1.05	-0.41	-0.08
Forecast			-0.7167	-0.6167	-0.6733	-1.0117	-1.1883	-1.0683	-1.045	-1.0283	-0.968	-1.03	-1.3177	-1.3514	-1.2605	-0.9783	-0.8917	-1.0771	-1.3206	-1.3199	-1.4686	-1.215	-1.1025	-0.95	-0.463	-0.3975
Surprise	0.00%	0.00%	+13.49%	-3.78%	-51.49%	-56.17%	+19.21%	+6.39%	+6.22%	+7.61%	-10.54%	-29.13%	-0.17%	+1.58%	+29.39%	+14.14%	+14.77%	-29.05%	-7.53%	-18.19%	+10.12%	+13.58%	-18.82%	-10.53%	+11.45%	+79.87%

Actual	--	--	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	682.00K	1.91M	7.32M	16.35M	29.66M	28.52M	39.50M	49.50M	57.58M
Forecast	--	--	0	0	0	0	0	0	0	0	211.00K	0	0	0	0	0	0	400.89K	1.63M	5.68M	12.61M	24.93M	29.02M	36.32M	46.99M	57.51M
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	+70.12%	+17.33%	+28.95%	+29.69%	+19.00%	-1.71%	+8.76%	+5.34%	+0.14%

PHAT

PHAT fundamentals

PHAT Q4 2025 Earnings

Earnings Call

You can ask Aime

PHAT

PHAT fundamentals

PHAT Q4 2025 Earnings

Earnings Call

PHAT Earnings Call Summary for Q4/20258:00 AM on Feb 26, 2026

PHAT Earnings Call Summary for Q3/20258:00 AM on Oct 30, 2025

PHAT Earnings Call Summary for Q2/20258:00 AM on Aug 7, 2025

PHAT Earnings Call Summary for Q1/20258:00 AM on May 1, 2025

PHAT Earnings Call Summary for Q4/20248:30 AM on Mar 6, 2025

You can ask Aime